Pharmaceutical Executive August 9, 2024
As part of the acquisition of CN201, Curon is expected to receive an upfront payment of $700 million, with the opportunity to earn an additional $600 million in milestone payments linked to the drug’s development and regulatory approval.
Merck has agreed to terms on the acquisition of CN201, a novel bispecific antibody aimed at treating B-cell associated diseases, developed by Curon Biopharmaceutical. According to Merck, full rights will be acquired through a subsidiary, providing Curon with an upfront payment of $700 million. Curon will be eligible for up to an additional $600 million pending the completion of milestones related to drug development and regulatory approval.1
“We continue to identify opportunities to expand and diversify our pipeline,” said Dean Y. Li,...
Today's Sponsors
Today's Sponsor